Comparing amidronate and immunosuppressive medications in treatment of patients with ankylosing spondylitis

Effect of amidronate and immunosuppressive medications in treatment of patients with ankylosing spondylitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017030813565N3

Enrollment

Registered

2017-05-06

Start date

2016-10-12

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing spondylitis. Ankylosing spondylitis

Interventions

Intervention 1: Pamidronate 90 mg IV Intervention group. Intervention 2: Retuximab 1000mg q14days two days control group.

Treatment - Drugs

Pamidronate 90 mg IV Intervention group

Retuximab 1000mg q14days two days control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: None of the patients were not received until study drug, PPD test and Viral markers were negative Exclusion criteria: the occurrence of side-effects; Patient unwillingness to continue the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CRP. Timepoint: 0,6m. Method of measurement: labratory.;BASDAI questionnaire. Timepoint: 0,6m. Method of measurement: BASDAI questionnaire.;BASFA questionnaire. Timepoint: 0,6m. Method of measurement: BASFA questionnaire.;ESR. Timepoint: 0,6m. Method of measurement: labratory.	—

Secondary

Measure	Time frame
HAQ questionnaire. Timepoint: 0,6. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Mohammad Reza Vaziri

Iran University of Medical Sciences

mrv6354@yahoo.com+98 21 54351

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026